199 related articles for article (PubMed ID: 30206771)
21. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
22. [ADH/D and impulsiveness: Prevalence of impulse control disorders and other comorbidities, in 81 adults with attention deficit/hyperactivity disorder (ADH/D)].
Porteret R; Bouchez J; Baylé FJ; Varescon I
Encephale; 2016 Apr; 42(2):130-7. PubMed ID: 26928277
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal analysis of impulse control disorders in Parkinson disease.
Corvol JC; Artaud F; Cormier-Dequaire F; Rascol O; Durif F; Derkinderen P; Marques AR; Bourdain F; Brandel JP; Pico F; Lacomblez L; Bonnet C; Brefel-Courbon C; Ory-Magne F; Grabli D; Klebe S; Mangone G; You H; Mesnage V; Lee PC; Brice A; Vidailhet M; Elbaz A;
Neurology; 2018 Jul; 91(3):e189-e201. PubMed ID: 29925549
[TBL] [Abstract][Full Text] [Related]
24. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
[TBL] [Abstract][Full Text] [Related]
25. Dopamine Agonists and Impulse Control Disorders: A Complex Association.
Grall-Bronnec M; Victorri-Vigneau C; Donnio Y; Leboucher J; Rousselet M; Thiabaud E; Zreika N; Derkinderen P; Challet-Bouju G
Drug Saf; 2018 Jan; 41(1):19-75. PubMed ID: 28861870
[TBL] [Abstract][Full Text] [Related]
26. Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature.
Sanjan G; Das L; Ahuja CK; Dhandapani S; Sachdeva N; Grover S; Dutta P
Neurol India; 2023; 71(1):107-112. PubMed ID: 36861582
[TBL] [Abstract][Full Text] [Related]
27. Prospective cohort study of impulse control disorders in Parkinson's disease.
Bastiaens J; Dorfman BJ; Christos PJ; Nirenberg MJ
Mov Disord; 2013 Mar; 28(3):327-33. PubMed ID: 23283708
[TBL] [Abstract][Full Text] [Related]
28. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
29. Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
Contin M; Lopane G; Marini L; Mohamed S; Sambati L; De Massis P; Guarino M; Sermi S; Persichella C; Cortelli P; Calandra-Buonaura G
Neurol Sci; 2023 Feb; 44(2):565-572. PubMed ID: 36350455
[TBL] [Abstract][Full Text] [Related]
30. Impulsivity in anxiety disorder patients: is it related to comorbid cyclothymia?
Perugi G; Del Carlo A; Benvenuti M; Fornaro M; Toni C; Akiskal K; Dell'Osso L; Akiskal H
J Affect Disord; 2011 Oct; 133(3):600-6. PubMed ID: 21665290
[TBL] [Abstract][Full Text] [Related]
31. Quality of life is decreased in female patients treated for microprolactinoma.
Kars M; van der Klaauw AA; Onstein CS; Pereira AM; Romijn JA
Eur J Endocrinol; 2007 Aug; 157(2):133-9. PubMed ID: 17656590
[TBL] [Abstract][Full Text] [Related]
32. Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity.
Pettorruso M; Fasano A; De Risio L; Ricciardi L; Di Nicola M; Martinotti G; Janiri L; Bentivoglio AR
J Neurol Sci; 2016 Mar; 362():344-7. PubMed ID: 26944176
[TBL] [Abstract][Full Text] [Related]
33. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study.
Vela L; Martínez Castrillo JC; García Ruiz P; Gasca-Salas C; Macías Macías Y; Pérez Fernández E; Ybot I; Lopez Valdés E; Kurtis MM; Posada Rodriguez IJ; Mata M; Ruiz Huete C; Eimil M; Borrue C; Del Val J; López-Manzanares L; Rojo Sebastian A; Marasescu R
J Neurol Sci; 2016 Sep; 368():150-4. PubMed ID: 27538621
[TBL] [Abstract][Full Text] [Related]
34. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology of impulse control disorders and association with dopamine agonist exposure, active component, U.S. Armed Forces, 2014-2018.
Garrett AR; Bazaco SL; Clausen SS; Oetting AA; Stahlman S
MSMR; 2019 Aug; 26(8):10-16. PubMed ID: 31442064
[TBL] [Abstract][Full Text] [Related]
36. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
Rizos A; Sauerbier A; Antonini A; Weintraub D; Martinez-Martin P; Kessel B; Henriksen T; Falup-Pecurariu C; Silverdale M; Durner G; Røkenes Karlsen K; Grilo M; Odin P; Chaudhuri KR;
Eur J Neurol; 2016 Aug; 23(8):1255-61. PubMed ID: 27170229
[TBL] [Abstract][Full Text] [Related]
37. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review.
Nakum S; Cavanna AE
Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525
[TBL] [Abstract][Full Text] [Related]
38. A prospective study on the association between caregiver psychological symptomatology and symptom clusters of pediatric posttraumatic stress disorder.
Wong SS; Kletter H; Wong Y; Carrion VG
J Trauma Stress; 2013 Jun; 26(3):385-91. PubMed ID: 23737297
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma.
Allard L; Albarel F; Bertherat J; Caron PJ; Cortet C; Courtillot C; Delemer B; Jublanc C; Maiter D; Nunes ML; Raverot G; Sarfati J; Salenave S; Corruble E; Choucha W; Chanson P
Eur J Endocrinol; 2020 Aug; 183(2):221-231. PubMed ID: 32583656
[TBL] [Abstract][Full Text] [Related]
40. Mucocele-like formation leading to neurological symptoms in prolactin-secreting pituitary adenomas under dopamine agonist therapy.
Abe T; Lüdecke DK
Surg Neurol; 1999 Sep; 52(3):274-9. PubMed ID: 10511086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
